Amgen (NASDAQ:AMGN) Stock Sale Reported by Sen. Sheldon Whitehouse

Key Points

• Sen. Sheldon Whitehouse disclosed selling his entire Amgen stake on October 15, valued in the filing at $15,001–$50,000.
• Amgen beat quarterly estimates, reporting EPS of $6.45 and revenue of $10.37 billion, up 8.5% year over year; the company also raised its full-year outlook.
• Despite the results, investor concerns about biosimilar competition weighed on shares, while an FDA warning letter over Vectibix promotion added a regulatory risk.

Senator Sheldon Whitehouse (Democratic-Rhode Island) recently sold their entire stake in Amgen Inc. NASDAQ: AMGN. In a filing disclosed on November 2nd, the Senator disclosed that they had sold between $15,001 and $50,000 in Amgen stock on October 15th.

Senator Sheldon Whitehouse also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 10/15/2026.
• Sold $1,001 - $15,000 in shares of Analog Devices NASDAQ: ADI on 9/4/2026.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 9/4/2026.
• Sold $15,001 - $50,000 in shares of JPMorgan Chase & Co. NYSE: JPM on 9/4/2026.
• Sold $15,001 - $50,000 in shares of NVIDIA NASDAQ: NVDA on 8/13/2026.
• Sold $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 8/13/2026.
• Sold $1,001 - $15,000 in shares of Lam Research NASDAQ: LRCX on 8/13/2026.
• Sold $1,001 - $15,000 in shares of Amgen NASDAQ: AMGN on 8/12/2026.

Amgen Stock Down 0.9%

Amgen stock opened at $461.26 on Wednesday. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The business's 50-day simple moving average is $420.83 and its two-hundred day simple moving average is $376.16. The company has a market cap of $249.37 billion, a PE ratio of 20.81, a PEG ratio of 3.41 and a beta of 0.43. Amgen Inc. has a fifty-two week low of $294.48 and a fifty-two week high of $475.64.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.79 by $0.66. The business had revenue of $10.37 billion during the quarter, compared to analysts' expectations of $10.07 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The company's revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.64 EPS. Equities analysts anticipate that Amgen Inc. will post 22.96 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen's payout ratio is presently 62.65%.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy Grygiel sold 2,970 shares of Amgen stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares of the company's stock, valued at $2,642,098.28. This trade represents a 23.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 6,222 shares of company stock valued at $2,540,926 over the last ninety days. 0.85% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

AMGN has been the subject of several research reports. Jefferies Financial Group reiterated a "hold" rating and set a $410.00 price objective on shares of Amgen in a research note on Wednesday, September 23rd. Canaccord Genuity Group lifted their price objective on Amgen from $366.00 to $384.00 and gave the company a "hold" rating in a research note on Wednesday, August 5th. Truist Financial raised their price objective on shares of Amgen from $362.00 to $380.00 and gave the company a "hold" rating in a research note on Wednesday, October 7th. Citigroup boosted their target price on Amgen from $345.00 to $405.00 and gave the stock a "neutral" rating in a research note on Friday, August 7th. Finally, Guggenheim lowered their target price on shares of Amgen from $388.00 to $378.00 and set a "neutral" rating for the company in a research note on Tuesday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $389.71.

Institutional Trading of Amgen

A number of institutional investors have recently bought and sold shares of AMGN. Quest 10 Wealth Builders Inc. boosted its stake in Amgen by 220.0% in the 3rd quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company's stock worth $34,000 after purchasing an additional 55 shares during the period. Wellington Altus USA Inc. lifted its holdings in shares of Amgen by 72.3% in the second quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company's stock worth $28,000 after buying an additional 34 shares in the last quarter. Nvwm LLC lifted its holdings in shares of Amgen by 412.5% in the third quarter. Nvwm LLC now owns 82 shares of the medical research company's stock worth $35,000 after buying an additional 66 shares in the last quarter. PFS Partners LLC lifted its holdings in shares of Amgen by 95.5% in the third quarter. PFS Partners LLC now owns 86 shares of the medical research company's stock worth $36,000 after buying an additional 42 shares in the last quarter. Finally, TOWER TRUST & INVESTMENT Co bought a new position in shares of Amgen during the third quarter worth $38,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen earned $6.45 per share on $10.37 billion in revenue, beating analyst estimates; revenue rose 8.5% year over year. The company also raised its outlook, with full-year revenue guidance slightly above the consensus estimate. Amgen Raises Outlook After 3Q Profit, Sales Rise
• Positive Sentiment: Sales growth in cholesterol and cancer medicines helped support the quarter, while the company’s broader growth portfolio was reported to be offsetting pressure from the denosumab product cycle. Amgen third quarter sales rise 8%, led by cholesterol, cancer drugs
• Negative Sentiment: Shares fell despite the earnings beat as investors focused on biosimilar competition facing key products, which could pressure future sales. Amgen beats estimates but shares dip on biosimilar concerns
• Negative Sentiment: The FDA issued Amgen a warning letter over promotion of its cancer drug Vectibix, adding a regulatory and reputational concern for investors. Amgen Gets FDA Warning Letter Over Misleading Vectibix Promotion

About Senator Whitehouse

Sheldon Whitehouse (Democratic Party) is a member of the U.S. Senate from Rhode Island. He assumed office on January 3, 2007. His current term ends on January 3, 2031. Whitehouse (Democratic Party) ran for re-election to the U.S. Senate to represent Rhode Island. He won in the general election on November 5, 2024.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company's products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.